Cantor Fitzgerald Reiterates “Overweight” Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $7.00 target price on the stock. Cantor Fitzgerald’s price objective indicates a potential upside of 189.26% from the company’s previous close.

Several other research firms have also recently weighed in on TSHA. Chardan Capital increased their price objective on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, March 21st. Piper Sandler assumed coverage on shares of Taysha Gene Therapies in a research note on Tuesday, April 9th. They set an “overweight” rating and a $9.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, April 11th. JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, March 21st. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $6.88.

Taysha Gene Therapies Stock Performance

Shares of Taysha Gene Therapies stock opened at $2.42 on Tuesday. The company has a 50 day moving average of $2.65 and a 200-day moving average of $2.09. Taysha Gene Therapies has a 1-year low of $0.50 and a 1-year high of $3.89. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 0.54. The company has a market cap of $452.59 million, a PE ratio of -3.61 and a beta of 0.29.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Tuesday, March 19th. The company reported $0.35 earnings per share (EPS) for the quarter. The business had revenue of $3.60 million during the quarter, compared to analyst estimates of $4.75 million. As a group, equities research analysts forecast that Taysha Gene Therapies will post -0.39 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. FMR LLC lifted its position in shares of Taysha Gene Therapies by 2,035.0% during the third quarter. FMR LLC now owns 24,527,801 shares of the company’s stock valued at $77,508,000 after purchasing an additional 23,378,974 shares in the last quarter. RA Capital Management L.P. bought a new position in shares of Taysha Gene Therapies during the third quarter valued at about $58,373,000. RTW Investments LP bought a new position in shares of Taysha Gene Therapies during the third quarter valued at about $53,382,000. Acuta Capital Partners LLC bought a new position in shares of Taysha Gene Therapies during the third quarter valued at about $12,096,000. Finally, Vanguard Group Inc. lifted its position in shares of Taysha Gene Therapies by 235.2% during the third quarter. Vanguard Group Inc. now owns 5,327,864 shares of the company’s stock valued at $16,836,000 after purchasing an additional 3,738,616 shares in the last quarter. 77.70% of the stock is owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.